Shares of CureVac (NASDAQ:CVAC – Get Free Report) dropped 5.8% during mid-day trading on Monday . The company traded as low as $3.52 and last traded at $3.57. Approximately 409,255 shares were traded during trading, a decline of 65% from the average daily volume of 1,157,037 shares. The stock had previously closed at $3.79.
CureVac Price Performance
The stock’s 50-day moving average price is $3.50 and its 200 day moving average price is $3.21. The firm has a market cap of $844.03 million, a price-to-earnings ratio of 6.85 and a beta of 2.51. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.
Institutional Investors Weigh In On CureVac
Several institutional investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC bought a new position in CureVac in the 3rd quarter valued at approximately $30,000. Integrated Wealth Concepts LLC bought a new position in shares of CureVac during the third quarter valued at $35,000. International Assets Investment Management LLC bought a new position in shares of CureVac during the third quarter valued at $35,000. Barclays PLC bought a new position in shares of CureVac during the third quarter valued at $67,000. Finally, Ballentine Partners LLC raised its stake in shares of CureVac by 58.6% during the third quarter. Ballentine Partners LLC now owns 22,755 shares of the company’s stock valued at $67,000 after acquiring an additional 8,406 shares during the last quarter. 17.26% of the stock is owned by institutional investors.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Further Reading
- Five stocks we like better than CureVac
- Investing In Automotive Stocks
- 3 Must-Have ETFs Set to Dominate This Quarter
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Seeking Stability? These 3 Stocks Offer Strong Potential
- How to Most Effectively Use the MarketBeat Earnings Screener
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
